Gary Patou, Director at Xenon Pharmaceuticals Inc. (XENE), sold 8,108 shares at $34.79 ($280K) on 2022-11-25, disclosed to the SEC on 2022-11-28.
Open-market sale of $280k XENE by Director. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $34.33 | 2,057 | $71K | 25.2% |
| 2 | $34.33 | 2,057 | $71K | 25.2% |
| 3 | $34.37 | 120 | $4K | 1.5% |
| 4 | $34.79 | 1,937 | $67K | 24.1% |
| 5 | $34.79 | 1,937 | $67K | 24.1% |
| Total | $34.55 avg | 8,108 |
| $280K |
| 100% |
| Filing → |
| XENE | SELL | 2023-12-15 | $1.0M | — | Filing → |
| XENE | SELL | 2023-12-15 | $624K | — | Filing → |
| XENE | BUY | 2017-08-14 | $21K | — | Filing → |